Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multiple-dose study of upadacitinib in pediatric polyarticular course juvenile idiopathic arthritis
jRCT2031220577Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2023
- Modality
- Small Molecules
01
Overview
Open-label trial of upadacitinib in juvenile idiopathic arthritis (JIA) (5 arms), sponsored by AbbVie Inc. Started Mar 2023; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on jRCT2031220577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220577.